Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication – Potential Increased Risk of Esophageal Cancer

Audience: Geriatrics, Family Practice, Internal Medicine Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate)
ISSUE: FDA notified…

Related posts:

1. Multaq (dronedarone): Drug Safety Communication – Increased Risk of Death or Serious Cardiovascular Events Audience: Healthcare Professionals ISSUE: FDA notified healthcare professionals that it...
2. CardioGen-82 PET Scan: Drug Safety Communication – Increased Radiation Exposure Audience: Nuclear Medicine, Radiology, Patients ISSUE: FDA notified the public...
3. Actos (pioglitazone): Ongoing Safety Review – Potential Increased Risk of Bladder Cancer Audience: Endocrinology, Family Practice, Urology [UPDATED 06/15/2011] Use of the diabetes...
4. Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication – Low Magnesium Levels Can Be Associated With Long-Term Use Audience: Consumer, Gastroenterology, Family Practice Prescription PPIs include Nexium (esomeprazole...